This trial is evaluating whether PET MRI will improve 1 primary outcome and 2 secondary outcomes in patients with Carcinoma, Hepatocellular. Measurement will happen over the course of 3 years.
This trial requires 20 total participants across 2 different treatment groups
This trial involves 2 different treatments. PET MRI is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
There was no obvious harm in the use of PET in cirrhotic patients with hepatocellular carcinoma and no sign of serious toxicity. However, there was not a chance to assess any improvement, so the potential value remained unclear. Therefore, we cannot confirm its use in cirrhotic patients with HCC in our practice.
Most patients with cirrhosis have no signs of carcinoma. The signs and symptoms of carcinoma are not the same in patients with cirrhosis or in patients with viral hepatitis.
A variety of anticancer agents including 5-Fu are used to treat HCC. In addition, Hepatitis B virus (HBV) infection-related HCC is treated with IFN-α, ALT, HBV-related drugs (such as lamivudine, adefovir dipivoxil, or entecavir) and radiotherapy, especially in cases without HCC, even if there is no concurrent HBV hepatitis.
The majority of persons with a prior diagnosis of CH, not ascertained to be an HCC at the diagnosis of CH, are likely to get another HCC.
Multiple genetic and environmental factors must interact in a complex manner to develop hepatocarcinoma. The role of hepatitis B virus, hepatitis C virus, HBV, and alcohol consumption is most well established.
The high overall survival rates following surgery in patients with hepatocellular carcinoma are surprising. Although these results are based on a relatively low number of patients, we believe that the low operative mortality and the long-term survival time warrant consideration for hepatocellular carcinoma in the adjuvant treatment protocol.
Cancer, hepatocellular, is a malignant tumor of the liver that originates from epithelia. Its primary cause is liver cirrhosis. Treatment is multimodal and is based on the type and stage of the tumor and associated liver disease.\n
One-off use of PET-MRI does not appear to be of benefit for detecting, staging and planning therapeutic intervention in patients with HCC. The clinical application of PET-MRI is currently limited by the relatively poor resolution and insufficient signal integrity associated with this form of imaging, and this restricts its application to selected patients who are sufficiently motivated to undertake the procedure. As such, PET-MRI cannot be regarded as a viable alternative to imaging with PET alone.
Liver cancers (especially HCCs) tend to occur later in life than previously appreciated, mainly due to improvements in imaging and detection technologies, but also partly due to an expanded lifespan.
PETM is an effective technique in improving quality of life in patients with carcinoma, hepatocellular. It should be offered to all inpatients who meet certain criteria for image quality enhancement.
There are two areas for research in hepatocellular carcinoma: 1. Hepatocellular carcinoma in cirrhosis and 2. HCC in non-cirrhotic livers. In particular, there are a number of molecules and proteins that are promising targets for research for hepatocellular carcinoma. Such molecules are the E2F- family, p53, Bcl-2, cyclin D1, and retinoblastoma protein in association with signal transduction networks.